Vutrisiran Dosage

Medically reviewed by Drugs.com. Last updated on Feb 23, 2023.

Usual Adult Dose for Hereditary Amyloidosis

Recommended dose: 25 mg administered by subcutaneous injection once every 3 months

Use: Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Renal Dose Adjustments

Mild and Moderate Renal Dysfunction: No adjustment recommended.
Severe Renal Dysfunction and End-Stage Renal Disease: Data not available

Liver Dose Adjustments

Mild Liver Dysfunction: No adjustment recommended.
Moderate and Severe Liver Dysfunction: Data not available

Precautions

US FDA requires a medication guide to assure safe use. For additional information: www.fda.gov/drugs/drug-safety-and-availability/medication-guides

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This drug is for subcutaneous administration only.
• Should be administered by a healthcare professional.
• Read the US FDA-approved patient labeling for further preparation and administration instructions.
• Vitamin A supplementation is recommended.

Storage requirements:

• Store at 2C to 30C (36F to 86F) in the original carton until ready for use.
• Do not freeze.

Monitoring:

• Vitamin A serum levels prior and during treatment

Patient advice:

• Read the Patient Information and Instructions for Use.
• Female patients should inform their healthcare provider if they are pregnant or planning to become pregnant while taking this drug.
• Patients should contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency such as night blindness.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer